The prospectus consists of ~4.21M shares issued to Covidien Group, ~1.81M shares issued to Ligand Pharmaceuticals in a private placement and ~2M shares issuable upon the exercise of a common stock purchase warrant dated August 4, 2025, with an exercise price of $3.67 per share.
The company will not receive any proceeds from the sale.


















